Latest Diabetes articles in the Big 4

BOOK REVIEW: Controversies in Treating Diabetes: Clinical and Research Aspects
Shortly before his election as president, John F. Kennedy wrote, "Let us welcome controversial books and controversial authors." To this statement we might add "and books on controversial medical topics," ...
New England Journal of Medicine - Jul 16, 2008 (2 days ago)

ORIGINAL CONTRIBUTION: Fetuin-A and Incident Diabetes Mellitus in Older Persons
...type 2 diabetes mellitus is unknown. Objective To determine whether fetuin-A levels are associated with incident diabetes in older persons. Design, Setting, and Participants Observational study among 3075 well-functioning persons aged 70 to 79 years. In this case-cohort study, we retrospectively measured fetuin-A levels in baseline serum among...
JAMA current issue - Jul 8, 2008 9:39 PM

β-cell transplantation for diabetes therapy
In their Comment, Piero Ruggenenti and colleagues outline why they have decided not to continue islet-cell transplantation. We wish to clarify several points for readers.
The Lancet - Jul 4, 2008 10:48 AM

β-cell transplantation for diabetes therapy – Authors' reply
In the largest series of islet transplant recipients treated with a common protocol of islet preparation and post-transplantation care (the Edmonton protocol), only 16 of 36 patients were still insulin-independent at 1 year; 10 had complete graft loss. Consistently, comparative studies have found that only 31% of islet recipients versus 96% of whol...
The Lancet - Jul 4, 2008 10:48 AM

β-cell transplantation for diabetes therapy
...treatment of diabetes.
The Lancet - Jul 4, 2008 10:48 AM

β-cell transplantation for diabetes therapy
Piero Ruggenenti and colleagues (March 15, p 883) highlight their failure to establish a clinical islet transplantation programme. Results of islet transplantation are similar to those of the early days of organ transplantation, where initial success rarely met with long-term function. The Edmonton protocol achieved reproducible insulin independenc...
The Lancet - Jul 4, 2008 10:48 AM

CORRECTIONS: Metformin versus Insulin for the Treatment of Gestational Diabetes
...of Gestational Diabetes . In the abstract (page 2003), under Results, the parenthetical information should read "(relative risk, 0.99; 95% confidence interval, 0.80 to ...
New England Journal of Medicine - Jul 2, 2008 10:20 PM

Book: Handle with care
...Primary Care Diabetes Society conference. I wanted to know more about the disease that, according to the 2002 report by Sir Derek Wanless, threatens to bankrupt the UK's National Health Service (NHS) over the next decade. It already costs the NHS more than £1 billion a year, most of which can be put down to failures in prevention and management ...
The Lancet - Jun 27, 2008 10:17 AM

Chronic kidney disease in Asia
...such as diabetes, hypertension, and metabolic syndrome, have become common and, as a result, chronic kidney disease has become a prevalent comorbidity in the past 10 years.
The Lancet - Jun 27, 2008 10:17 AM

Type 2 diabetes: pathogenesis and treatment
...type 2 diabetes mellitus, several important developments have taken place. Further evidence that the disease has a strong hereditary component led to a vigorous search to identify candidate genes (). This approach uncovered two prevalent polymorphisms (in addition to PPARy and KCNJ11). HNF1B (MODY5) bears a polymorphism associated with type 2 di...
The Lancet - Jun 27, 2008 10:17 AM

[RESEARCH] Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2
...type 2 diabetes, renal disease, atrial fibrillation, and rheumatoid arthritis. Results The validation statistics indicated that QRISK2 had improved discrimination and calibration compared with the modified Framingham score. The QRISK2 algorithm explained 43% of the variation in women and 38% in men compared with 39% and 35%, respectively, by the...
BMJ current issue - Jun 27, 2008 12:09 AM

Latest Diabetes News from the National Library for Health

MeReC Monthly (June 2008): Self-monitoring in type 2 diabetes
via NeLM news - Diabetes on 7/7/08
The latest edition of MeReC Monthly reviews the use of routine self-monitoring of blood glucose (SMBG), noting that two recent studies (ESMON and DiGEM economic analysis) have reinforced the view that it is unlikely to be beneficial in patients with type 2 diabetes who are not treated with insulin and may worsen quality of life and waste NHS resources. Therefore it should be reserved for patients treated with insulin and for non-insulin treated patients in specific circumstances, as recommended in recent NICE guidance on type 2 diabetes (see link).

SMC accepts restricted use of Eucreas tablets (vildagliptin 50mg + metformin 850mg or 1000mg) for type 2 diabetes
via NeLM news - Diabetes 7/7/08
Following a review of an abbreviated submission (used for new formulations at same or lesser cost, and new tablet strength or size), the Scottish Medicines Consortium (SMC) has accepted for restricted use within NHS Scotland, Eucreas® tablets (vildagliptin 50mg/metformin 850mg and vildagliptin 50mg /metformin 1000mg). ...

Meta-analysis: Pregabalin for painful diabetic neuropathy
via NeLM news - Diabetes on 6/7/08
Pregabalin is effective for treatment of painful diabetic neuropathy across its usual dose range, according to a meta-analysis sponsored by the drug's manufacturer and part-authored by company employees. A number of controlled trials have been carried out with pregabalin in patients with painful diabetic neuropathy, however they have used different dose regimens: this analysis was carried out to evaluate the drug's efficacy and safety in this condition at all effective doses....

DTB: exenatide (Byetta), sitagliptin (Januvia), and vildagliptin (Galvus) for type 2 diabetes
via NeLM news - Diabetes on 6/7/08
The July edition of the Drug and Therapeutics Bulletin (DTB) features a review of three new treatments for type 2 diabetes: exenatide (Byetta®), sitagliptin (Januvia®), and vildagliptin (Galvus®). It discusses the incretins and glucose metabolism, examines the trial data and its limitations, and looks at national guidelines....

FDA panel says diabetes drugs need cardiovascular risk studies
via NeLM news - Diabetes on 2/7/08
PharmaTimes reports that the US Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee has advised US regulators they should insist that studies on new diabetes treatments include much more data on the potential heart risks of the treatments....

FDA to consider necessity of cardiovascular studies for diabetes drugs
via NeLM news - Diabetes on 30/6/08
According to a report in the Wall Street Journal, the US FDA is summoning a panel of experts to consider whether pharmaceutical companies should be required to study the cardiovascular effects of diabetes drugs prior to approval. The report points out that cardiovascular endpoints are relatively rare and therefore large, long-term studies would be required to demonstrate any statistically significant effects; this could slow the development of new drugs and would increase costs.

FDA approves PrandiMet (repaglinide and metformin) for type 2 diabetes
via NeLM news - Diabetes on 24/6/08
According to BioSpace, the FDA has approved PrandiMet™ (repaglinide and metformin) tablets as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus who are already treated with a meglitinide [the drug class that repaglinide belongs to] and metformin or who have inadequate glycaemic control on a meglitinide alone or metformin alone. Please see the link above for details.

Benefits of intensive glucose control in older type 2 diabetics limited by co-morbidity
via NeLM news - Diabetes on 30/6/08
A decision analysis study suggests that for older patients with type 2 diabetes, intensive blood glucose control becomes less useful with increasing co-morbidity and functional impairment; chronological age alone, however, was not useful for predicting benefit. Intensive control of blood glucose has been shown to be beneficial in type 1 diabetes, and may also improve outcomes in type 2 diabetes....

25 June 2008 - My life
via NLH Diabetes Specialist Library Whats New by Diane Clay on 25/6/08
How to manage your diabetes as a young adult, moving away from home, taking control of your life


NPC iblog: Putting blood glucose control in type 2 diabetes into perspective
via NeLM news - Diabetes on 16/6/08
The National Prescribing Centre have published an iblog discussing a “Perspective” article published in the New England Journal of Medicine, that discusses the implications of ACCORD and ADVANCE studies, alongside some other major clinical studies that evaluated the benefits of reducing risk factors, such as blood lipids, blood pressure and blood glucose levels on preventing cardiovascular (CV) disease....

Antipsychotic agents and diabetes: meta-analysis plus study data on aripiprazole
via NeLM news - Diabetes by nelm@gstt.nhs.uk on 15/6/08
Second-generation antipsychotic drugs are associated with a small increase in risk of diabetes compared to first-generation drugs, according to a meta-analysis, although retrospective analysis of data from a clinical trial suggests that an increased risk with aripiprazole may be less likely....

15 June 2008 - Interesting new diabetes papers April 2008
via NLH Diabetes Specialist Library Whats New on 15/6/08
The latest edition of Dr Roger Gadsbys bulletin is now available

11 June 2008 - Diabetic retinopathy screening
via NLH Diabetes Specialist Library Whats New on 11/6/08
Statement published by the Department of Health on 3 April 2008

11 June 2008 - Joint Position Statement - Integrated Care in the Reforming NHS
via NLH Diabetes Specialist Library Whats New on 11/6/08
A joint publication by Diabetes UK, the Association of British Clinical Diabetologists (ABCD), the Primary Care Diabetes Society (PCDS), Community Diabetes Consultants (CDC) and the RCN Diabetes Nursing Forum issued in December 2007

Diabetes, Vol 57, Part 6

We have full text to this journal - click on here to access the journal online. You will need your Athens password to sign in.


A rare mutation in ABCC8/SUR1 leading to altered ATP-sensitive K^+channel activity and beta-cell glucose sensing is associated with type 2 diabetes in adults
Author(s):Tarasov , A . I . ; Nicolson , T . J . ; Riveline , J . - P . ; Taneja , T . K . ; Baldwin , S . A . ; Baldwin , J . M . ; Charpentier , G . ; Gautier , J . - F . ; Froguel , P . ; Vaxillaire , M .
ISSUE:2008 ; VOL 57 ; PART 6
Page:
1595-1604


Critical roles for macrophages in islet angiogenesis and maintenance during pancreatic degeneration
Author(s):Tessem , J . S . ; Jensen , J . N . ; Pelli , H . ; Dai , X . - M . ; Zong , X . - H . ; Stanley , E . R . ; Jensen , J . ; Degregori , J .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1605-1617


Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion
Author(s):Braun , M . ; Ramracheya , R . ; Bengtsson , M . ; Zhang , Q . ; Karanauskaite , J . ; Partridge , C . ; Johnson , P . R . ; Rorsman , P .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1618-1628


Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice
Author(s):Belmadani , S . ; Palen , D . I . ; Gonzalez - Villalobos , R . A . ; Boulares , H . A . ; Matrougui , K .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1629-1637


beta-Cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test
Author(s):Festa , A . ; Williams , K . ; Hanley , A . J . G . ; Haffner , S . M .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1638-1644

Retinal and cerebral microvascular signs and diabetes: the Age, Gene/Environment Susceptibility-Reykjavik Study
Author(s):Qiu , C . ; Cotch , M . F . ; Sigurdsson , S . ; Garcia , M . ; Klein , R . ; Jonasson , F . ; Klein , B . E . K . ; Eiriksdottir , G . ; Harris , T . B . ; Van Buchem , M . A .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1645-1650

Suppressors of cytokine-signaling proteins induce insulin resistance in the retina and promote survival of retinal cells
Author(s):Liu , X . ; Mameza , M . G . ; Lee , Y . S . ; Eseonu , C . I . ; Yu , C . - R . ; Derwent , J . J . K . ; Egwuagu , C . E .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1651-1658

Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations
Author(s):Kapoor , R . R . ; Locke , J . ; Colclough , K . ; Wales , J . ; Conn , J . J . ; Hattersley , A . T . ; Ellard , S . ; Hussain , K .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1659-1663

Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model
Author(s):Brussee , V . ; Guo , G . ; Dong , Y . ; Cheng , C . ; Martinez , J . A . ; Smith , D . ; Glazner , G . W . ; Fernyhough , P . ; Zochodne , D . W .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1664-1673

Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes
Author(s):Goldberg , L . J . ; Hu , Y . ; Noh , H . - L . ; Wei , J . ; Huggins , L . A . ; Rackmill , M . G . ; Hamai , H . ; Reid , B . N . ; Blaner , W . S . ; Huang , L . - S .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1674-1682

RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease
Author(s):Peng , F . ; Wu , D ; Gao , B . ; Ingram , A . J . ; Zhang , B . ; Chorneyko , K . ; McKenzie , R . ; Krepinsky , J . C .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1683-1692


Abnormal muscle spindle innervation and large-fiber neuropathy in diabetic mice
Author(s):Muller , K . A . ; Ryals , J . M . ; Feldman , E . L . ; Wright , D . E .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1693-1701

Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes
Author(s):Costacou , T . ; Ferrell , R . E . ; Orchard , T . J .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1702-1706


Having one kidney does not accelerate the rate of development of diabetic nephropathy lesions in type 1 diabetic patients
Author(s):Chang , S . ; Caramori , M . L . ; Moriya , R . ; Mauer , M .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1707-1711


Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy
Author(s):Mima , A . ; Arai , H . ; Matsubara , T . ; Abe , H . ; Nagai , K . ; Tamura , Y . ; Torikoshi , K . ; Araki , M . ; Kanamori , H . ; Takahashi , T
ISSUE:2008 ; VOL 57 ; PART 6
Page:1712-1722

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
Author(s):Han , S . ; Hagan , D . L . ; Taylor , J . R . ; Xin , L . ; Meng , W . ; Biller , S . A . ; Wetterau , J . R . ; Washburn , W . N . ; Whaley , J . M .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1723-1729

PTPN22 Trp^ 6^ 2^ 0 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes
Author(s):Smyth , D . J . ; Cooper , J . D . ; Howson , J . M . M . ; Walker , N . M . ; Plagnol , V ; Stevens , H . ; Clayton , D . G . ; Todd , J . A .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1730-1737


Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes
Author(s):Holmkvist , J . ; Almgren , P . ; Lyssenko , V . ; Lindgren , C . M . ; Eriksson , K . - F ; Isomaa , B . ; Tuomi , T . ; Nilsson , P . ; Groop , L .
ISSUE:2008 ; VOL 57 ; PART 6
Page:1738-1744


The diabetic phenotype in HNF4A mutation carriers is moderated by the expression of HNF4A isoforms from the P1 promoter during fetal development
Author(s):Harries , L . W . ; Locke , J . M . ; Shields , B . ; Hanley , N . A . ; Hanley , K . P . ; Steele , A . ; Njolstad , P . R . ; Ellard , S . ; Hattersley , A . T
ISSUE:2008 ; VOL 57 ; PART 6
Page:
1745-1752


Sequencing-based genotyping and association analysis of the MICA and MICB genes in type 1 diabetes
Author(s):Field , S . F . ; Nejentsev , S . ; Walker , N . M . ; Howson , J . M . M . ; Godfrey , L M . ; Jolley , J . D . ; Hardy , M . P . A . ; Todd , J . A
ISSUE:2008 ; VOL 57 ; PART 6
Page:1753-1756